Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL2367279 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL336363 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL13517377 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL5019049 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL2553076 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL336361 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL1130719 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL12648656 | 1.00 | TSHR (0.56) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL16237980 | 0.97 | TSHR (0.53) | TSHRSLC7A5USP2SLCO1B1SLC1A3 | |
| D,L-Threo-3-Hydroxyaspartic Acid SCHEMBL8200338 | 0.97 | TSHR (0.53) | TSHRSLC7A5USP2SLCO1B1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 931 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | claimed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | claimed |
| EP-4295866-A2 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2023-12-27 | — | — | EP | claimed |
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | claimed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | claimed |
| CN-114728044-A | Modified factor VII polypeptides for subcutaneous administration and on-demand treatment | 介控生化科技公司 | 2022-07-08 | — | — | CN | claimed |
| US-20210187083-A1 | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT | OAKTREE FUND ADMINISTRATION, LLC | 2021-06-24 | — | — | US | claimed |
| EP-3833381-A1 | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT | Catalyst Biosciences, Inc. (US) | 2021-06-16 | — | — | EP | claimed |
| US-20210101941-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2021-04-08 | — | — | US | claimed |
| US-20210069306-A1 | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT | GC BIOPHARMA CORP. (KR) | 2021-03-11 | — | — | US | claimed |
| US-5648455-A | TREATMENT OF DRUG RESISTANT BACTERIA | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-07-15 | — | — | US | claimed |
| CN-1132252-A | Antibiotic WAP-8294A, process for its preparation and antibacterial composition | WAKAMOTO PHARMA CO LTD (JP) | 1996-10-02 | — | — | CN | claimed |
| US-5518906-A | MUTANT ESCHERICHIA MICROBE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | claimed |
| EP-0668358-A1 | Antibiotic WAP-8294A, method for preparing the same and antibacterial composition | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1995-08-23 | — | — | EP | claimed |
| CN-1095105-A | Production of D-pantoic acid and D-pantothenic acid | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-11-16 | — | — | CN | claimed |
| EP-0590857-A2 | Production of D-pantoic acid and D-pantothenic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-06 | — | — | EP | claimed |
| WO-1992019717-A1 | A HIGH-AFFINITY HUMAN GLUTAMATE/ASPARTATE UPTAKE SYSTEM | BAYLOR COLLEGE OF MEDICINE (US) | 1992-11-12 | — | — | WO | claimed |
| US-4452782-A | IMMUNOPOTENTIATING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | claimed |
| EP-0019072-B1 | PENTADECAPEPTIDE, PROCESS FOR THE PREPARATION THEREOF AND IMMUNOPOTENTIATING AGENT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-09-14 | — | — | EP | claimed |
| EP-0019072-A1 | Pentadecapeptide, process for the preparation thereof and immunopotentiating agent | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | TSHR 2352/4885SLC7A5 2179/4885USP2 1775/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | TSHR 1073/4885SLC7A5 196/4885USP2 1530/4885 |
| US-20210101941-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | QPCT, QPCTL, VIP | TSHR 2209/4885SLC7A5 277/4885USP2 1808/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | TSHR 1606/4885SLC7A5 37/4885USP2 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.